Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815180 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B1HSD17B2MAPTCYP1A1 | |
| SCHEMBL4214562 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B1HSD17B2MAPTCYP1A1 | |
| SCHEMBL6206966 | 0.89 | ALDH1A1 (0.44) | ALDH1A1HSD17B1HSD17B2MAPTMEN1 | |
| SCHEMBL1786969 | 0.89 | ALDH1A1 (0.44) | ALDH1A1HSD17B1HSD17B2MAPTMEN1 | |
| SCHEMBL3205373 | 0.85 | TSHR (0.49) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL3806023 | 0.85 | TSHR (0.49) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL3805744 | 0.85 | EPHX1 (0.47) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL5205180 | 0.85 | TSHR (0.49) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4214493 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNA | |
| SCHEMBL3222025 | 0.84 | TSHR (0.46) | ALDH1A1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| US-7524856-B2 | Tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1465/4885HSD17B1 2178/4885HSD17B2 2219/4885 |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ACKR3, CXCR1, CXCR2 | ALDH1A1 707/4885HSD17B1 507/4885HSD17B2 588/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1375/4885HSD17B1 2046/4885HSD17B2 2044/4885 |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 946/4885HSD17B1 475/4885HSD17B2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.